<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601184</url>
  </required_header>
  <id_info>
    <org_study_id>MEVITEM</org_study_id>
    <secondary_id>2011-003372-37</secondary_id>
    <nct_id>NCT01601184</nct_id>
  </id_info>
  <brief_title>Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway</brief_title>
  <official_title>An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of vismodegib in combination with
      temozolomide (primary objective - phase I) and to estimate the efficacy of vismodegib in
      combination with temozolomide in adult patients with recurrent, progressive, or refractory
      medulloblastomas to standard therapy measured by the 6-month progression-free rate (phase
      II).

      This study is an open-label Phase I/II, international, randomized.

      38 patients will be included in the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives are :

      phase I : to collect preliminary results on the 6-month progression-free rate of the
      combination vismodegib + temozolomide

      PHASE II

      To estimate in the two study arms:

        -  the objective response rate (Complete response + Partial Response according to WHO
           criteria) after 6 months of treatment

        -  the duration of treatment response

        -  the best overall response obtained during the study

        -  the progression-free survival (PFS)

        -  the time to progression (TTP)

        -  the time to treatment failure (TTF)

        -  In the combination arm (vismodegib + temozolomide): to further evaluate the safety of
           the combination.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of a fixed dose of vismodegib in combination with (phase I)temozolomide in adult patients with recurrent, progressive, or refractory to standard therapy medulloblastoma</measure>
    <time_frame>during the first three months follow up</time_frame>
    <description>number of severe toxicities occurring during the first 3 months of follow-up :
Toxic death
Grade 4 toxicity
Any grade 3 AE leading to study treatment interruption for more than 7 days or discontinuation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To estimate the efficacy of vismodegib in combination with temozolomide in adult patients with recurrent, progressive, or refractory to standard therapy medulloblastoma (phase II)</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>the 6-month progression-free rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To collect preliminary results on the 6-month progression-free rate of the combination vismodegib + temozolomide (phase I)</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>measurement of progression free rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate in the two study arms the objective response rate after 6 months of treatment (phase II)</measure>
    <time_frame>after 6 months of treatment</time_frame>
    <description>measure by objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate in the two study arms the duration of treatment response (phase II)</measure>
    <time_frame>one year</time_frame>
    <description>treatment response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate in the two study arms the best overall response obtained during the study (phase II)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate in the two study arms the progression-free survival (PFS)(phase II)</measure>
    <time_frame>one year</time_frame>
    <description>measure of progression free rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate in the two study arms the time to treatment failure (phase II)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of adverse events based on the common toxicity criteria (CTC-AE-V4.0) grade</measure>
    <time_frame>one year</time_frame>
    <description>In the combination arm (vismodegib + temozolomide): to further evaluate the safety of the combination</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Histologically Confirmed Medulloblastoma</condition>
  <condition>Activation of the Sonic Hedgehog (SHH) Pathway</condition>
  <arm_group>
    <arm_group_label>combination of vismodegib with temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive
- Arm A: the combination of vismodegib (150 mg/day continuously) with temozolomide (150 mg/m2 during Cycle 1 [day 1 to day 5/ 28 day-cycle] and 200 mg/m2 during subsequent cycles) (6 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>temozolomide alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive Arm B: temozolomide alone (150 mg/m2 day1 to day 5/ 28 day-cycle during Cycle 1 and 200 mg/m2 day 1 to day 5/ 28 day-cycle during subsequent cycles) (3 patients).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vismodegib alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Considering the rarity of the disease, the few therapeutic options available and the promising results reported with vismodegib in adult medulloblastoma : the Sponsor will consider (on case by case basis) the enrolment of patients previously treated by temozolomide in a 3rd independent and parallel study arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vismodegib</intervention_name>
    <description>Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day</description>
    <arm_group_label>combination of vismodegib with temozolomide</arm_group_label>
    <arm_group_label>vismodegib alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days</description>
    <arm_group_label>combination of vismodegib with temozolomide</arm_group_label>
    <arm_group_label>temozolomide alone</arm_group_label>
    <other_name>temodal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patients must have histologically confirmed medulloblastoma (including posterior fossa
             primitive neuroectodermal tumor) for which no known curative therapy exists

          -  Patients must have recurrent or refractory disease

          -  Patients must have evidence of measurable disease or lesion in pre-inclusion MRI.
             Patients with measurable spinal disease are eligible. NB: Patients with complete
             resection for recurrence are not eligible.

          -  Activation of the SHH pathway validated by IHC.

          -  ECOG performance status 0, 1 or 2

          -  Life expectancy ≥ 12 weeks

          -  Patients must have normal organ and marrow function as defined below:

        Neutrophils ≥ 1. 5 G/L Platelets ≥ 100 G /L Hemoglobin ≥ 10g/dL Creatinine clearance ≥ 50
        mL/min (calculated by Cockcroft-Gault formula or MDRD formula for patients older than 65
        years ) or serum creatinine within normal limits or less than 1.5 x upper limit of normal
        (ULN) Total bilirubin ≤ 1.5 ULN ALAT and ASAT ≤ 2.5 ULN Serum albumin ≥ 25 g/L.

          -  Patients recovered from prior treatment-related toxicity (persistent treatment related
             toxicity &lt;Grade 2 are allowed (NCI-CTCAE v4.0).

          -  Prior therapy:

        No prior hedgehog antagonist vismodegib or other antagonists of the hedgehog pathway, and
        no prior temozolomide treatment for patients to be randomized in Arm A or B. Patients
        previously treated with temozolomide are eligible for enrollment in study arm C on a case
        by case basis and following sponsor agreement More than 4 weeks since prior
        myelosuppressive chemotherapy (6 weeks for nitrosoureas, 6 months after high dose therapy)
        or immunotherapy At least 3 months since prior craniospinal irradiation (≥ 23 Gy) At least
        8 weeks since prior local irradiation to primary tumor At least 2 weeks since prior focal
        irradiation for symptomatic metastatic sites.

        At least 1 week since prior colony-stimulating factors (e.g., G-CSF, GM-CSF, or
        erythropoietin)

          -  Women of childbearing potential* are required to have a negative serum pregnancy test
             within 72 hours prior to study treatment initiation (i.e. Cycle 1 Day 1).

             *: Female patients who meet at least one of the following criteria are defined as
             women of non-childbearing potential:

             ≥50 years old and naturally amenorrheic for ≥ 1 year Permanent premature ovarian
             failure confirmed by a specialist gynaecologist Previous bilateral
             salpingo-oophorectomy XY genotype, Turner's syndrome, or uterine agenesis Female
             patient who do not meet at least of the above criteria are defined as women of
             childbearing potential.

          -  An embryo-fetal development study in rats has confirmed the teratogenic potential of
             vismodegib. Therefore, women of child-bearing potential and men must use two forms of
             effective contraception (including one barrier method- refer to Appendix 4 for
             acceptable method of contraception) at least 4 weeks prior to study entry, during the
             study period and for at least 24 months post-treatment for women and 2 months
             post-treatment for men. Prior to dispensing vismodegib, the investigator must confirm
             and document the patient's use of two contraceptive methods, dates of negative
             pregnancy test, and confirm the patient's understanding of the teratogenic potential
             of vismodegib.

          -  Ability to understand and willingness to comply to follow-up visits.

          -  Covered by a medical insurance (in countries where applicable)

        Exclusion Criteria:

          -  Tumor tissue sample not available for biological studies (from the initial diagnosis
             and/or relapse)

          -  Pregnant or breastfeeding women are not eligible.

          -  History of allergic reactions attributed to compounds of similar chemical composition
             to vismodegib.

          -  Any contraindications to temozolomide treatment as per Temodal® SPC (see Appendix 5).

          -  Patients with malabsorption syndrome or other condition that would interfere with
             intestinal absorption. Patients must be able to swallow capsules.

          -  Uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, or hypokalemia, defined as
             less than the lower limit of normal despite adequate electrolyte supplementation.

          -  History of congestive heart failure.

          -  History of ventricular arrhythmia requiring medication.

          -  Congenital long QT syndrome.

          -  Clinically significant unrelated systemic illness (e.g., serious infection or
             significant cardiac, pulmonary, hepatic, or other organ dysfunction) that would
             compromise the patient's ability to tolerate study treatment or would likely interfere
             with study procedures or results.

          -  Patients using prohibited concomitant and/or concurrent medications (see section
             &quot;Prohibited concomitant/concurrent treatments.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>didier frappaz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Léon Bérard, Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Didier Frappaz</last_name>
    <phone>+ 33 478 78 28 81</phone>
    <email>didier.frappaz@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <state>Bouches Du Rhône</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>olivier chinot, Pr</last_name>
      <phone>+33 4 91 38 55 00</phone>
      <email>olivier.chinot@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Chinot, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maryline Barrié, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chantal Campello, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emeline Tabouret, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Régaud (iuct-oncopole)</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne LAPRIE, Dr</last_name>
      <phone>+33 5 31 15 54 43</phone>
      <email>laprie.anne@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Anne LAPRIE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra BENOUAICH-AMIEL, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne DUCASSOU, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Laigle-Donadey, DR</last_name>
      <phone>+33 1 42 16 03 81</phone>
      <email>florence.laigle-donadey@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Florence Laigle-Donadey, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Yves DELATTRE, PR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khê HOANG-XUAN, PR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc SANSON, PR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline DEHAIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dimitri PSIMARAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline HOUILLER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed IDBAIH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie TAILLIBERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - René Gauducheau</name>
      <address>
        <city>St Herblain</city>
        <state>Loire Atlantique</state>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Campone, Pr</last_name>
      <phone>+33 2 40 67 99 77</phone>
      <email>mario.campone@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Mario Campone, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Sébastien Frenel, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole Gourmelon, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akila BENINE-DANDEC, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie ROBERT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Central de Nancy</name>
      <address>
        <city>Nancy</city>
        <state>Meurthe Et Moselle</state>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHBS Hôpital du Scorff</name>
      <address>
        <city>Lorient</city>
        <state>Morbihan</state>
        <zip>56322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie LE RHUN, Dr</last_name>
      <phone>+33 3 20 29 59 35</phone>
      <email>emilie.lerhun@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Emilie LE RHUN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François DUBOIS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <state>Rhone</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Frappaz, Dr</last_name>
      <phone>+33 4 78 782 881</phone>
      <email>didier.frappaz@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Didier Frappaz, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Pierre Sunyach, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves Devaux, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice LEVARD, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CASSIER, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BELLARIA Ospedale</name>
      <address>
        <city>Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alba BRANDES, Dr</last_name>
      <email>a.brandes@ausl.bo.it</email>
    </contact>
    <investigator>
      <last_name>Alba BRANDES, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco BARTOLOTTI, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrico FRANCESHI, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosalba POGGI, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Turin</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Riccardo SOFFIETTI, Dr</last_name>
      <email>riccardo.soffietti@unito.it</email>
    </contact>
    <investigator>
      <last_name>Riccardo SOFFIETTI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberta RUDA, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa TREVISAN, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas HOTTINGER, Dr</last_name>
      <email>andreas.hottinger@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Krisztian HOMISCO, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas HOTTINGER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael WELLER, Pr</last_name>
      <email>Michael.Weller@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Michael WELLER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roger STUPP, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ghazaleh TABATABAI, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michaela TONDER, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans-Georg WIRSCHING, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick ROTH, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tobias WEISS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospital - Mount Vernon Cancer Centre - Mount Vernon hospital</name>
      <address>
        <city>London</city>
        <zip>London-NW1-2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul MULHOLLAND, Dr</last_name>
      <email>paul.mulholland@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Paul MULHOLLAND, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Lupi O. Correlations between the Sonic Hedgehog pathway and basal cell carcinoma. Int J Dermatol. 2007 Nov;46(11):1113-7. Review.</citation>
    <PMID>17988327</PMID>
  </reference>
  <reference>
    <citation>Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, Connelly M, Stewart CF, Gould S, Rubin LL, Curran T. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell. 2004 Sep;6(3):229-40.</citation>
    <PMID>15380514</PMID>
  </reference>
  <reference>
    <citation>Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, Marshall D, Fu L, Januario T, Kallop D, Nannini-Pepe M, Kotkow K, Marsters JC, Rubin LL, de Sauvage FJ. A paracrine requirement for hedgehog signalling in cancer. Nature. 2008 Sep 18;455(7211):406-10. doi: 10.1038/nature07275. Epub 2008 Aug 27.</citation>
    <PMID>18754008</PMID>
  </reference>
  <reference>
    <citation>Cornu P, Chatellier G, Fauchon F, Foncin JF, Faillot T, Dorwling-Carter D, Philippon J. [The prognosis of medulloblastoma in adults]. Neurochirurgie. 1990;36(4):218-24. Review. French.</citation>
    <PMID>2277658</PMID>
  </reference>
  <reference>
    <citation>Coulbois S, Civit T, Grignon Y, Taillandier L, Girard F, Marchal C, Pinelli C, Auque J. [Adult medulloblastoma. Review of 22 patients]. Neurochirurgie. 2001 Feb;47(1):6-12. French.</citation>
    <PMID>11283450</PMID>
  </reference>
  <reference>
    <citation>Giordana MT, Schiffer P, Lanotte M, Girardi P, Chio A. Epidemiology of adult medulloblastoma. Int J Cancer. 1999 Mar 1;80(5):689-92.</citation>
    <PMID>10048968</PMID>
  </reference>
  <reference>
    <citation>Brandes AA, Palmisano V, Monfardini S. Medulloblastoma in adults: clinical characteristics and treatment. Cancer Treat Rev. 1999 Feb;25(1):3-12. Review.</citation>
    <PMID>10212586</PMID>
  </reference>
  <reference>
    <citation>Chan AW, Tarbell NJ, Black PM, Louis DN, Frosch MP, Ancukiewicz M, Chapman P, Loeffler JS. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery. 2000 Sep;47(3):623-31; discussion 631-2.</citation>
    <PMID>10981749</PMID>
  </reference>
  <reference>
    <citation>del Charco JO, Bolek TW, McCollough WM, Maria BL, Kedar A, Braylan RC, Mickle JP, Buatti JM, Mendenhall NP, Marcus RB Jr. Medulloblastoma: time-dose relationship based on a 30-year review. Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):147-54.</citation>
    <PMID>9747832</PMID>
  </reference>
  <reference>
    <citation>Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist. 2004 Nov;10(6):293-310. Review.</citation>
    <PMID>15518596</PMID>
  </reference>
  <reference>
    <citation>Padovani L, Sunyach MP, Perol D, Mercier C, Alapetite C, Haie-Meder C, Hoffstetter S, Muracciole X, Kerr C, Wagner JP, Lagrange JL, Maire JP, Cowen D, Frappaz D, Carrie C. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):433-40.</citation>
    <PMID>17498567</PMID>
  </reference>
  <reference>
    <citation>Abacioglu U, Uzel O, Sengoz M, Turkan S, Ober A. Medulloblastoma in adults: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):855-60.</citation>
    <PMID>12377339</PMID>
  </reference>
  <reference>
    <citation>Carrie C, Lasset C, Alapetite C, Haie-Meder C, Hoffstetter S, Demaille MC, Kerr C, Wagner JP, Lagrange JL, Maire JP, et al. Multivariate analysis of prognostic factors in adult patients with medulloblastoma. Retrospective study of 156 patients. Cancer. 1994 Oct 15;74(8):2352-60.</citation>
    <PMID>7922986</PMID>
  </reference>
  <reference>
    <citation>Evans AE, Jenkin RD, Sposto R, Ortega JA, Wilson CB, Wara W, Ertel IJ, Kramer S, Chang CH, Leikin SL, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg. 1990 Apr;72(4):572-82.</citation>
    <PMID>2319316</PMID>
  </reference>
  <reference>
    <citation>Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, Mulne L, Boyett J, D'Angio G, Wechsler-Jentzsch K, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994 Nov;81(5):690-8.</citation>
    <PMID>7931615</PMID>
  </reference>
  <reference>
    <citation>Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006 Sep 1;24(25):4202-8.</citation>
    <PMID>16943538</PMID>
  </reference>
  <reference>
    <citation>Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris-Jones P. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer. 1990 Apr;26(4):464-9.</citation>
    <PMID>2141512</PMID>
  </reference>
  <reference>
    <citation>Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, Allen JC, Stevens KR, Stanley P, Li H, Wisoff JH, Geyer JR, McGuire-Cullen P, Stehbens JA, Shurin SB, Packer RJ. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999 Mar;17(3):832-45.</citation>
    <PMID>10071274</PMID>
  </reference>
  <reference>
    <citation>Riffaud L, Saikali S, Leray E, Hamlat A, Haegelen C, Vauleon E, Lesimple T. Survival and prognostic factors in a series of adults with medulloblastomas. J Neurosurg. 2009 Sep;111(3):478-87. doi: 10.3171/2009.1.JNS081004.</citation>
    <PMID>19231932</PMID>
  </reference>
  <reference>
    <citation>Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50.</citation>
    <PMID>17705175</PMID>
  </reference>
  <reference>
    <citation>Barone G, Maurizi P, Tamburrini G, Riccardi R. Role of temozolomide in pediatric brain tumors. Childs Nerv Syst. 2006 Jul;22(7):652-61. Epub 2006 Mar 25. Review.</citation>
    <PMID>16565851</PMID>
  </reference>
  <reference>
    <citation>Kenney AM, Rowitch DH. Sonic hedgehog promotes G(1) cyclin expression and sustained cell cycle progression in mammalian neuronal precursors. Mol Cell Biol. 2000 Dec;20(23):9055-67.</citation>
    <PMID>11074003</PMID>
  </reference>
  <reference>
    <citation>Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001 Dec 1;15(23):3059-87. Review.</citation>
    <PMID>11731473</PMID>
  </reference>
  <reference>
    <citation>Hooper JE, Scott MP. Communicating with Hedgehogs. Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17. Review.</citation>
    <PMID>15803137</PMID>
  </reference>
  <reference>
    <citation>Ferretti E, De Smaele E, Di Marcotullio L, Screpanti I, Gulino A. Hedgehog checkpoints in medulloblastoma: the chromosome 17p deletion paradigm. Trends Mol Med. 2005 Dec;11(12):537-45. Epub 2005 Nov 14. Review.</citation>
    <PMID>16290230</PMID>
  </reference>
  <reference>
    <citation>Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009 Jun;30(6):303-12. doi: 10.1016/j.tips.2009.03.007. Epub 2009 May 13. Review.</citation>
    <PMID>19443052</PMID>
  </reference>
  <reference>
    <citation>Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov. 2006 Dec;5(12):1026-33. Review.</citation>
    <PMID>17139287</PMID>
  </reference>
  <reference>
    <citation>Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 2003 Dec;3(12):903-11. Review.</citation>
    <PMID>14737121</PMID>
  </reference>
  <reference>
    <citation>Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-72. doi: 10.1056/NEJMoa0905360. Epub 2009 Sep 2.</citation>
    <PMID>19726763</PMID>
  </reference>
  <reference>
    <citation>Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009 Sep 17;361(12):1173-8. doi: 10.1056/NEJMoa0902903. Epub 2009 Sep 2.</citation>
    <PMID>19726761</PMID>
  </reference>
  <reference>
    <citation>Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011 Mar;121(3):381-96. doi: 10.1007/s00401-011-0800-8. Epub 2011 Jan 26.</citation>
    <PMID>21267586</PMID>
  </reference>
  <reference>
    <citation>Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, Ryan SL, Lusher ME, Taylor MD, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC. Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res. 2011 Apr 1;17(7):1883-94. doi: 10.1158/1078-0432.CCR-10-2210. Epub 2011 Feb 16.</citation>
    <PMID>21325292</PMID>
  </reference>
  <reference>
    <citation>Steg A, Vickers SM, Eloubeidi M, Wang W, Eltoum IA, Grizzle WE, Saif MW, Lobuglio AF, Frost AR, Johnson MR. Hedgehog pathway expression in heterogeneous pancreatic adenocarcinoma: implications for the molecular analysis of clinically available biopsies. Diagn Mol Pathol. 2007 Dec;16(4):229-37.</citation>
    <PMID>18043287</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>medulloblastoma</keyword>
  <keyword>sonic hedgehog pathway</keyword>
  <keyword>vismodegib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

